<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eslicarbazepine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eslicarbazepine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eslicarbazepine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="91586" href="/d/html/91586.html" rel="external">see "Eslicarbazepine: Drug information"</a> and <a class="drug drug_patient" data-topicid="91896" href="/d/html/91896.html" rel="external">see "Eslicarbazepine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F23905581"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aptiom</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871679"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aptiom</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F51258639"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F50641650"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7da4c65-4d37-47cf-9f8d-0c86c1a7d4bb">Seizures, partial onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, partial onset (monotherapy or adjunctive): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents ≤17 years: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">11 to 21 kg: Initial: 200 mg once daily; may increase in weekly increments of no more than 200 mg<b>/day</b>, titrate based on clinical response and tolerability; maintenance dose: 400 to 600 mg once daily; maximum daily dose: 600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">22 to 31 kg: Initial: 300 mg once daily; may increase in weekly increments of no more than 300 mg/<b>day</b>, titrate based on clinical response and tolerability; maintenance dose: 500 to 800 mg once daily; maximum daily dose: 800 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">32 to 38 kg: Initial: 300 mg once daily; may increase in weekly increments of no more than 300 mg/<b>day</b>, titrate based on clinical response and tolerability; maintenance dose: 600 to 900 mg once daily; maximum daily dose: 900 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;38 kg: Initial: 400 mg once daily; may increase in weekly increments of no more than 400 mg/<b>day</b>, titrate based on clinical response and tolerability; maintenance dose: 800 to 1,200 mg once daily; maximum daily dose: 1,200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral: Initial: 400 mg once daily, may initiate at 800 mg once daily if seizure reduction outweighs risk of adverse reactions during initiation. May increase in weekly increments of 400 to 600 mg/<b>day</b>, titrate dose based on clinical response and tolerability; maintenance dose: 800 to 1,600 mg once daily; maximum dose: 1,600 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128332"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: Reduce all doses (initial, titration increments, maintenance) by 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ESRD) undergoing hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Repeated dialysis removes metabolites.</p></div>
<div class="block dohp drugH1Div" id="F51128333"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment during therapy: Increased transaminases and bilirubin without evidence of obstruction, patients with jaundice, or other evidence of significant liver injury: Discontinue therapy.</p></div>
<div class="block doa drugH1Div" id="F22788775"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="91586" href="/d/html/91586.html" rel="external">see "Eslicarbazepine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31008289-31f3-4083-91b3-0190ad6d466a">Focal onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>Oral:</b> 400 mg once daily; may initiate treatment at 800 mg once daily if seizure reduction outweighs risk of adverse reactions during initiation. Increase in weekly increments of 400 to 600 mg based on clinical response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance:<b> Oral:</b>
<i></i>800 to 1,600 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy: </i>Consider 800 mg once daily for maintenance therapy in patients not tolerating 1,200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjunctive therapy: </i>Consider 1,600 mg once daily for maintenance therapy in patients not achieving response on 1,200 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Unless safety concerns require a more rapid withdrawal, reduce dosage gradually and avoid abrupt discontinuation in order to minimize the risk of increased seizure frequency and status epilepticus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991592"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: Administer 50% of normal initial, titration and maintenance doses; may base titration and maintenance dosage adjustments on clinical response.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis, intermittent (thrice weekly): There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Repeated dialysis removes metabolites.</p></div>
<div class="block doha drugH1Div" id="F50988804"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment: Use is not recommended (has not been studied). </p></div>
<div class="block adr drugH1Div" id="F23647648"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for adjunctive therapy in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (10% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (20% to 28%), drowsiness (11% to 28%), headache (13% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (9% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (2%), peripheral edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), constipation (2%), diarrhea (4%), gastritis (2%), vomiting (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (2%), asthenia (3%), ataxia (4% to 6%), balance impairment (3%), cognitive dysfunction (4% to 7%), depression (3%), dysarthria (1% to 2%), falling (3%), fatigue (7%), insomnia (2%), memory impairment (1% to 2%), tremor (2% to 4%), vertigo (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5% to 6%), nystagmus disorder (1% to 2%), visual impairment (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia, increased LDL cholesterol, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolongation P-R interval on ECG (mild) (Vas-Da-Silva 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Severe dermatological reaction (including Stevens-Johnson syndrome and toxic epidermal necrolysis) (Alcántara-Reifs 2016; Massot 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased T3 level, decreased T4 (free and total), SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, megaloblastic anemia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (&gt;2 × ULN), increased serum transaminases (&gt;3 × ULN)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, drug reaction with eosinophilia and systemic symptoms (Willikens 2019)</p></div>
<div class="block coi drugH1Div" id="F22769678"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to eslicarbazepine, oxcarbazepine, or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to carbamazepine; history or presence of second- or third-degree atrioventricular block</p></div>
<div class="block war drugH1Div" id="F22788762"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Use has been associated with dose-dependent CNS-related adverse events, most significant of these were cognitive symptoms (eg, memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, psychomotor retardation), somnolence or fatigue, dizziness and coordination abnormalities (eg, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, abnormal coordination), and visual changes (eg, diplopia, blurred vision, impaired vision). There was an increased risk of visual changes and dizziness and coordination abnormalities during the titration period, in patients &gt;60 years of age, and with concomitant carbamazepine use; consider dosage modifications in patients using eslicarbazepine and carbamazepine concomitantly. Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Potentially serious, sometimes fatal, dermatologic reactions including Stevens-Johnson syndrome (SJS) have been reported; monitor for signs and symptoms of skin reactions; discontinuation and conversion to alternate therapy may be required. Avoid use in patients with prior dermatologic reaction with carbamazepine, oxcarbazepine, or eslicarbazepine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Cases of pancytopenia, agranulocytosis, and leukopenia have been reported; consider discontinuing eslicarbazepine if these hematologic abnormalities develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic effects ranging from mild to moderate elevations in transaminases (&gt;3 times the upper limit of normal) to rare cases of concomitant elevations of total bilirubin (&gt;2 times the upper limit of normal) have been reported. Perform baseline liver laboratory tests. Discontinue in patients with jaundice or other evidence of significant liver injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Rare cases of anaphylaxis and angioedema have been reported. Permanently discontinue should symptoms occur. Avoid use in patients with a prior anaphylactic-type reaction with either oxcarbazepine or eslicarbazepine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyponatremia: Clinically significant hyponatremia (serum sodium &lt;125 mmol/L) and concurrent hypochloremia may develop during use. In controlled trials, effects were dose-related, appeared within the first 8 weeks of treatment (as early as after 3 days), and resolved without additional treatment within a few days of eslicarbazepine discontinuation. Consider monitoring serum sodium and chloride levels during maintenance treatment, especially in patients at risk for hyponatremia and if symptoms of hyponatremia develop. Depending on the severity of hyponatremia, the dose of eslicarbazepine may need to be reduced or discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, have been reported. Monitor for signs and symptoms (eg, fever, rash, lymphadenopathy, eosinophilia) in association with other organ system involvement (eg, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis). Evaluate immediately if signs or symptoms are present. Discontinuation and conversion to alternate therapy may be required. Avoid use in patients with a prior DRESS reaction with carbamazepine, oxcarbazepine, or eslicarbazepine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; patients should be instructed to notify healthcare provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid function: Dose-dependent decreases in serum T<sub>3</sub> and T<sub>4</sub> (free and total) values have been observed; changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Clearance is decreased in patients with impaired renal function; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Avoid use in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block foc drugH1Div" id="F23905582"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptiom: 200 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptiom: 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptiom: 600 mg, 800 mg [scored]</p></div>
<div class="block geq drugH1Div" id="F23905580"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F24144989"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aptiom Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $50.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $50.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $50.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $50.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871680"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aptiom: 200 mg, 400 mg, 600 mg, 800 mg</p></div>
<div class="block admp drugH1Div" id="F52614549"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food; tablets may be swallowed whole or crushed.</p></div>
<div class="block adm drugH1Div" id="F22788777"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with or without food; tablets may be swallowed whole or crushed.</p></div>
<div class="block hazard drugH1Div" id="F49104480"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F22788763"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline"> Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block meg drugH1Div" id="F23620856"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;">An FDA-approved medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:0em;margin-left:2em;">Aptiom: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F022416s009lbl.pdf%23page%3D26&amp;token=sgue1VRxbi89Ggz7GyoGbygumNXFKXUfgNw5jUgqe6qDYKJA3gRa7dqrDus1Xxxk%2FOlJf%2BqOLVycdWTN%2B9pczTV1%2BhevRAXIU9XZKguhIkSmsPTbVcNNhSXAxpe9OvUA&amp;TOPIC_ID=117807" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022416s009lbl.pdf#page=26</a></p></div>
<div class="block usep drugH1Div" id="F53571112"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Monotherapy or adjunctive therapy in the treatment of partial-onset seizures (FDA approved in patients ≥4 years and adults)</p></div>
<div class="block cyt drugH1Div" id="F22813025"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of UGT2B4; <b>Inhibits</b> CYP2C19 (weak); <b>Induces</b> BCRP/ABCG2, CYP3A4 (moderate), OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F22813022"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the adverse/toxic effect of Eslicarbazepine. CarBAMazepine may decrease the serum concentration of Eslicarbazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: BCRP/ABCG2 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: Eslicarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider alternatives to eslicarbazepine in patients treated with cobicistat. If coadministration cannot be avoided, monitor for loss of virologic response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Encorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Eslicarbazepine. (based on studies with phenytoin) Eslicarbazepine may increase the serum concentration of Fosphenytoin. (based on studies with phenytoin)<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Antiseizure Agents (Sodium Channel Blockers) may enhance the arrhythmogenic effect of LamoTRIgine.  Management: Consider the risk of serious arrhythmias or death versus any expected benefit of lamotrigine in patients receiving concomitant sodium channel blockers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirmatrelvir and Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: Eslicarbazepine may enhance the adverse/toxic effect of OXcarbazepine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Eslicarbazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Eslicarbazepine. Eslicarbazepine may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Eslicarbazepine. (based on studies with phenobarbital)<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Eslicarbazepine may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Eslicarbazepine may decrease the serum concentration of Warfarin. Specifically, S-warfarin serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inducers may decrease the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49168434"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Eslicarbazepine may decrease plasma concentrations of hormonal contraceptives; additional or alternative nonhormonal contraceptives are recommended in women of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F22788760"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to eslicarbazepine during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53571113"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Seizure frequency; liver enzymes (baseline, periodically); serum sodium and chloride as deemed necessary during maintenance treatment (particularly in patients receiving other medications known to decrease sodium levels or if symptoms of hyponatremia develop); symptoms of CNS depression (dizziness, disturbance in gait and coordination, somnolence); visual changes; periodic thyroid function tests (pediatric patients); hypersensitivity reactions. Monitor for suicidality (eg, suicidal thoughts, anxiety, depression, behavioral changes). For adjunctive therapy, serum levels of concomitant antiseizure drugs during titration as necessary.</p></div>
<div class="block pha drugH1Div" id="F22788764"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline"> Eslicarbazepine acetate is extensively converted to eslicarbazepine, which is considered responsible for therapeutic effects. A precise mechanism has not been defined, but is thought to involve inhibition of voltage-gated sodium channels.</p></div>
<div class="block phk drugH1Div" id="F22788765"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.87 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;40%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly and extensively metabolized by hydrolytic first-pass metabolism to the major active metabolite eslicarbazepine and minor active metabolites (R)-licarbazepine and oxcarbazepine; active metabolites are further metabolized to inactive glucuronides.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: &gt;90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Pediatric patients 4 to 17 years: 10 to 16 hours; Adults: 13 to 20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Eslicarbazepine: Pediatric patients 4 to 17 years: 1 to 3 hours; Adults: 1 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (90%; ~66% eslicarbazepine, ~33% glucuronide conjugate forms, ~10% other minor metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51154055"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a single 800 mg dose, systemic exposure was increased by 62% with mild renal impairment (CrCl 50 to 80 mL/minute), 2-fold with moderate renal impairment (CrCl 30 to 49 mL/minute), and 2.5-fold with severe renal impairment (CrCl &lt;30 mL/minute).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23672182"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aptiom</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eslibon | Zebinix</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Eslicar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Eslibon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eslibon | Zebinix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eslibon | Eslicarbazepin Aristo | Eslicarbazepin beta | Eslicarbazepin Heumann | Eslicarbazepin neuraxpharm | Zebinix</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Eslicarba | Eslizepine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arupsan | Bixcar | Escarpilo | Eslicarbazep stada | Eslicarbazepina acetato aristo | Eslicarbazepina Alter | Eslicarbazepina Cinfa | Eslicarbazepina normon | Eslicarbazepina tecnigen | Eslicarbazepina teva | Feoxan | Lizmin | Zebinix | Zekilep</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arupsan | Zebinix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Esran | Zebinix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eslicarbazepine meditop | Zebinix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Eslicar | Eslify | Eslistar | Eslizen | Zefretol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arupsan | Eslicarbazepin doc | Zebinix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eslibon | Zebinix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aptiom</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acetato de eslicarbazepina alter | Acetato de eslicarbazepina mylan | Acetato de eslicarbazepina pentafarma | Acetato de eslicarbazepina pharmakern | Bixcar | Zebinix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Elicarbax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zebinix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Exalief</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arupsan | Eslicarbazepine acetate aristo | Zebinix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Eslibon | Zebinix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USNF.1">
<a name="USNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27160801">
<a name="27160801"></a>Alcántara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo G, de la Corte-Sánchez S, Vélez García-Nieto A. Eslicarbazepine-induced toxic epidermal necrolysis. <i>Epilepsia</i>. 2016;57(5):854-855. doi:10.1111/epi.13363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eslicarbazepine-pediatric-drug-information/abstract-text/27160801/pubmed" id="27160801" target="_blank">27160801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aptiom.1">
<a name="Aptiom.1"></a>Aptiom (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aptiom.2">
<a name="Aptiom.2"></a>Aptiom (eslicarbazepine) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25422574">
<a name="25422574"></a>Massot A, Gimenez-Arnau A. Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine. <i>J Pharmacol Pharmacother</i>. 2014;5(4):271-274. doi:10.4103/0976-500X.142456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eslicarbazepine-pediatric-drug-information/abstract-text/25422574/pubmed" id="25422574" target="_blank">25422574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf" target="_blank">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21415284">
<a name="21415284"></a>Vaz-Da-Silva M, Nunes T, Almeida L, Gutierrez MJ, Litwin JS, Soares-Da-Silva P. Evaluation of eslicarbazepine acetate on cardiac repolarization in a thorough QT/QTc study. <i>J Clin Pharmacol</i>. 2012;52(2):222-233. doi:10.1177/0091270010391789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eslicarbazepine-pediatric-drug-information/abstract-text/21415284/pubmed" id="21415284" target="_blank">21415284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31541846">
<a name="31541846"></a>Willikens S, Wolking S. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) under treatment with eslicarbazepine. <i>Seizure</i>. 2019;72:11-12. doi:10.1016/j.seizure.2019.06.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eslicarbazepine-pediatric-drug-information/abstract-text/31541846/pubmed" id="31541846" target="_blank">31541846</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117807 Version 146.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
